Crossmark

Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN

Published Online: 2020-09-21

Published Print: 2020-11

Authors

Bell, Stacie

Merola, Joseph F.

Webster, Dan E.

Pennington, Stephen R.

Liao, Wilson

Ogdie, Alexis

FitzGerald, Oliver

Ritchlin, Christopher

Scher, Jose U. https://orcid.org/0000-0002-1072-6994
Funding

Funding for this research was provided by:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR074500-01A, U01-AI119125)

National Psoriasis Foundation

National Psoriasis Foundation
License Information

Text and Data Mining valid from 2020-09-21

Version of Record valid from 2020-09-21
More Information

Article History

First Online: 21 September 2020

Compliance with Ethical Standards

:

: UCB, Janssen, Abbvie, Pfizer, Novartis, Sanofi, BMS (Scher); AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Corrona (Ogdie); AbbVie, Lilly, Janssen, Novartis, BMS, Pfizer, Amgen, UCB (FitzGerald); Abbvie, Amgen, Janssen, Novartis, Pfizer, Regeneron, and TRex Bio (Liao)BMS, Abbvie, Dermavant, Lilly, Novartis, Janssen, UCB, Sun Pharma, Pfizer, EMD Sorono (Merola). Novartis, Janssen, Pfizer, Otsuka (Webster).

: As this is a review article, this article does not contain any studies with human or animal subjects.

Document is current